Clobetasol Propionate Foam, 0.05%
Olux Foam (Prestium Pharma, Inc)
Renaissance Pharma introduces Clobetasol Propionate Foam, 0.05%, a generic equivalent to Stiefel Laboratories’ Olux Foam. It is indicated for the short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatosis of the scalp, and for short-term treatment of mild to moderate plaque-type psoriasis on nonscalp regions, excluding the face and intertriginous areas. It can be applied twice per day, once in the morning and once at night.
Foam: 50 and 100 g
For More Information: www.RenaissancePharmaInc.com
Moxifloxacin Hydrochloride Tablets
Avelox Tablets (Bayer HealthCare Pharmaceuticals, Inc)
Teva Pharmaceuticals announces the introduction and availability of moxifloxacin hydrochloride tablets, an AB-rated equivalent to Avelox Tablets. It is a fluoroquinolone antibacterial indicated for treating infections caused by designated susceptible bacteria in adults 18 years and older. The recommended dose is 400 mg once a day. The duration of therapy varies by infection type; further information can be found in the full prescribing information.
Tablets: 400 mg
For More Information: www.TevaGenerics.com
Prochlorperazine Edisylate Injection
Heritage Pharmaceuticals, Inc
Compazine (GlaxoSmithKline; discontinued)
Heritage Pharmaceuticals Inc announces the immediate availability of prochlorperazine edisylate injection in the mg/mL strength. It is the AP-rated generic equivalent to the former brand Compazine. Prochlorperazine edisylate injecton is indicated for the treatment of severe nausea and vomiting and for the treatment of schizophrenia. It should be administered intramuscularly or intravenously; subcutaneous administration is not advisable due to local irritation.
Injectable vial: 5 mg/mL
For More Information: www.heritagepharma.com
Hectorol (Genzyme Corporation)
Roxane Laboratories announces the availability of doxercalciferol capsules, an AB-rated equivalent to Genzyme’s Hectorol capsules. They are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, and for the treatment of secondary hyperparathyroidism in patients with stage-3 or -4 chronic kidney disease. The recommended initial dose of doxercalciferol capsules is 10 mcg administered 3 times weekly at dialysis, approximately every other day.
Capsules: 0.5, 1, and 2.5 mcg
For More Information: www.roxane.com